Welcome to our dedicated page for 20/20 Biolabs SEC filings (Ticker: AIDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
20/20 BioLabs filings document the company's diagnostics business, public-company registration, operating results, and capital structure. Its registration statements describe the AIDX issuer as an emerging growth company and smaller reporting company, with disclosures covering the OneTest laboratory-testing business, risk factors, securities registration, and Nasdaq listing context.
Its Form 8-K reports cover material events such as financial-results announcements and financing arrangements, including secured convertible promissory notes and warrants. The filings also provide formal records of corporate governance, securities issuance, offering-related disclosures, and other matters associated with a commercial-stage diagnostics company operating a CAP-accredited and CLIA-licensed laboratory.
20/20 Biolabs, Inc. (NASDAQ: AIDX) furnished an investor webinar presentation outlining its multi-cancer early detection strategy, regulatory engagement, and commercial progress for its OneTest platform. The materials emphasize integration of serial biomarker testing, machine learning, and anti-inflammatory lifestyle interventions, and discuss potential positioning for future Medicare coverage of multi-cancer early detection blood tests beginning in 2028.
The company reports that Q2 2026 produced its best quarterly cancer testing revenue to date, with a 47% year-over-year increase, driven by 29 orders from new occupational health and clinical accounts and expanding firefighter screening programs in Maryland and Vermont. 20/20 Biolabs also describes preliminary, non-binding discussions with senior FDA personnel about evidence generation and potential regulatory pathways, and outlines planned next steps including formal interactions such as informational meetings, possible Breakthrough Device designation requests, and Q-Submissions, while cautioning that requirements, timing, and outcomes may differ materially from current expectations.
20/20 Biolabs, Inc. (AIDX) reported the results of its August 18, 2026 annual stockholders meeting held via webcast. Stockholders of record on June 22, 2026, holding 12,251,198 common shares, were entitled to vote, and 4,256,837 shares were represented, constituting a quorum.
Six directors were elected, each receiving roughly 2.65–2.73 million votes for and about 156–176 thousand votes withheld, with 1,433,721 broker non-votes on each director. Stockholders ratified dbbmckennon as independent registered public accounting firm for 2026 with 4,105,584 votes for, 132,421 against, and 18,832 abstentions. They also approved the 2026 Equity Incentive Plan with 2,183,335 votes for, 573,931 against, 65,850 abstentions, and 1,433,721 broker non-votes, and approved the ability to adjourn the meeting if needed, by 3,037,106 votes for, 1,132,166 against, and 87,565 abstentions. A charter amendment proposal did not receive sufficient votes and the meeting was adjourned on that item to September 16, 2026.
20/20 Biolabs, Inc. is updating its resale registration covering up to 15,164,724 shares of common stock held by certain selling stockholders, incorporating its quarterly results for the period ended June 30, 2026.
For the quarter, revenue rose to $730,571 from $535,060, driven mainly by higher OneTest cancer-screening sales, especially to Maryland firefighter programs. Gross margin improved to 41.71% from 30.51%. However, higher public-company, stock-based compensation and investor-relations costs pushed operating expenses to $1.55 million, widening the quarterly net loss to $1.51 million versus $0.84 million a year earlier.
For the first six months, revenue was essentially flat at $1.08 million, while the net loss increased to $3.68 million from $1.61 million, reflecting increased operating and financing costs, including losses tied to convertible notes and warrant-related derivatives. As of June 30, 2026, the company held $4.55 million in cash and cash equivalents and $2.52 million in working capital, supported by a $6.0 million Series E preferred stock financing and related convertible debt transactions. Management notes recent losses may continue and that failure to secure adequate capital could eventually force a cessation of operations.
20/20 Biolabs, Inc. is updating a resale registration statement covering up to 10,105,000 shares of common stock held by selling stockholders, while incorporating its quarterly results for the period ended June 30, 2026. The common stock trades on Nasdaq under “AIDX,” closing at $0.549 on August 14, 2026, with 12,770,303 shares outstanding.
For the second quarter, revenue rose to $730,571, up 36.54% year over year, driven mainly by 47.08% growth in OneTest sales, while quarterly gross margin improved to 41.71%. However, higher public-company and growth-related costs pushed the quarterly net loss to $1,506,343; the six‑month net loss reached $3,681,180.
Liquidity improved through a $6,000,000 private placement of Series E convertible preferred stock, lifting cash to $4,546,140 and working capital to $2,524,386. As of June 30, 2026, 5,228 Series E preferred shares were outstanding, senior to common stock and convertible into common shares, alongside 3,656,172 outstanding warrants, creating potential future dilution.
20/20 BioLabs, Inc. reported strong top-line improvement for the quarter ended June 30, 2026. Revenue rose 36.5% to $730,571 from $535,060, driven by OneTest™ multi-cancer early detection blood tests, which increased 47.1% to $697,034 and represented 95.3% of total revenue.
Gross profit grew 86.6% to $304,727, with gross margin expanding to 41.7% from 30.5%, reflecting favorable mix and better fixed-cost absorption. However, operating expenses increased to $1.55 million from $1.01 million, largely due to Nasdaq listing costs and product development spend, leading to a quarterly net loss of $1.51 million versus $0.84 million a year earlier.
For the first half of 2026, revenue was essentially flat at $1.08 million, while net loss widened to $3.68 million. Liquidity improved meaningfully: cash rose to $4.55 million at June 30, 2026 from $1.03 million at year-end 2025, primarily from $6.0 million of Series E preferred financing, and all convertible note debt was eliminated. Stockholders’ equity turned positive at $1.62 million from a slight deficit.
20/20 Biolabs, Inc. reported higher Q2 2026 revenues but significantly larger losses. Revenue for the quarter was $730,571, up 36.5% year over year, driven mainly by strong growth in OneTest sales, particularly from Maryland firefighter cancer screening programs. Q2 gross margin improved to 41.71% from 30.51% as lab fixed costs were leveraged over higher volumes.
For the six months ended June 30, 2026, revenue was $1,083,946, roughly flat with 2025, while the net loss widened to $3,681,180 from $1,605,511 due to higher public-company and listing-related expenses, increased research and development, and financing-related costs including interest and derivative losses. Cash and cash equivalents rose to $4,546,140, supported by a $6 million Series E preferred private placement and new convertible debt, giving working capital of $2,524,386.
Management notes recent operating losses are expected to continue near term and states that if additional capital cannot be obtained, operations could cease, indicating going concern uncertainty despite the recent capital raises. Capital structure became more complex, with legacy preferred shares and convertible notes converted into common stock and 5,228 shares of Series E convertible preferred stock outstanding plus 3.66 million warrants.
20/20 Biolabs, Inc. outlines materials used in an August 5, 2026 investor webinar describing U.S. legislation creating the Multi-Cancer Early Detection Screening Coverage Act, which gives CMS authority to reimburse multi-cancer blood tests beginning in 2028. Management believes its OneTest multi-cancer assay could be positioned for Medicare reimbursement if it obtains FDA authorization and meets CMS clinical appropriateness criteria.
The presentation contrasts OneTest’s 12‑marker protein and inflammation panel, serial testing three times per year, and machine‑learning “velocity” algorithms with ctDNA approaches such as Grail’s Galleri, noting that Galleri’s randomized NHS‑Galleri trial of over 142,000 participants missed its primary endpoint and has a $949 list price. Exact Sciences’ Cologuard revenue ramp from $2M to $266M after Medicare coverage is used only as a contextual analogy.
Business updates include preliminary, unaudited indications that Q2 2026 produced the company’s best quarterly cancer testing revenue to date, 29 orders from new accounts, a Maryland firefighter screening program covering 18 departments and more than 1,400 participants, and selection for a Vermont program to screen up to 4,500 firefighters. The company describes a three‑month Giant Food pilot for its longevity test, a roll‑up M&A strategy targeting companies with $2–$8 million in annualized revenue, and hypothetical revenue projections that imply a 5% royalty pool of about $100 million over five years to be shared pro‑rata with “data investors,” all expressly conditioned on achieving regulatory and reimbursement milestones.
20/20 Biolabs, Inc. entered a standstill agreement with Streeterville Capital related to its previously arranged offering of up to $40,000,000 of Series E convertible preferred stock at $1,000 per share. For 120 days from July 16, 2026, Streeterville agrees not to convert Series E preferred shares into common stock unless the trading price is at least 10% greater than the Nasdaq “Minimum Price”, with the standstill ending upon any breach of the agreement or an Event of Default.
The company also received a Nasdaq notice of non-compliance with the $1.00 minimum bid price requirement after its shares closed below $1.00 for 30 consecutive business days from June 3, 2026 to July 16, 2026. 20/20 Biolabs has until January 13, 2027 to regain compliance by maintaining a closing bid of at least $1.00 for 10 consecutive business days, with the possibility of an additional 180-day period or eventual delisting if compliance is not restored.
20/20 Biolabs, Inc. used this report to share an investor presentation on its OneTest multi‑cancer early detection strategy, focused on potential future Medicare reimbursement. The company highlights the new Multi‑Cancer Early Detection Screening Coverage Act, which creates a pathway for Medicare coverage of multi‑cancer blood tests starting in 2028 for FDA‑authorized products deemed appropriate by CMS.
The presentation contrasts protein‑based OneTest with ctDNA competitors and describes a serial biomarker‑tracking model that uses 12 cancer and inflammation markers, velocity algorithms, and an anti‑inflammatory diet program. It cites modeled early‑stage sensitivity improvements with more frequent testing and real‑world data from over 35,000 U.S. firefighters by the end of 2026. Management also outlines an M&A strategy targeting health‑and‑wellness businesses with $2–$8 million in annual revenue and includes illustrative revenue projections and a 5% royalty pool for “data investors,” all explicitly labeled as hypothetical and contingent on obtaining FDA authorization and Medicare reimbursement.
20/20 Biolabs, Inc. is asking stockholders at its August 18, 2026 virtual annual meeting to elect six directors, ratify its auditor, approve a major charter change and adopt a new equity plan. Holders of 12,251,198 common shares as of June 22, 2026 can vote online, by phone, fax or mail.
The company seeks approval to amend its certificate of incorporation to increase authorized common stock from 50 million to 500 million shares and remove converted preferred stock series. It explains this is to ensure enough shares for potential conversions of series E preferred stock and future corporate purposes.
Stockholders are also asked to approve a 2026 Equity Incentive Plan covering 5,000,000 shares, with an automatic annual increase equal to 7% of shares outstanding, to grant options and other awards to employees, consultants and directors. The proxy also requests authority to adjourn the meeting if more time is needed to solicit votes and outlines standard governance practices, board independence and executive/director compensation.